Perdagangan HOOKIPA Pharma Inc. - HOOK CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | 0.0502 | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.030779% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | -0.013666% | ||||||||
Waktu biaya inap | 22:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | USD | ||||||||
Margin | 20% | ||||||||
Bursa efek | United States of America | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
Key Stats
Prev. Close* | 0.9784 |
Open* | 0.9804 |
1-Year Change* | -28.44% |
Day's Range* | 0.9784 - 1 |
52 wk Range | 0.72-3.05 |
Average Volume (10 days) | 201.04K |
Average Volume (3 months) | 6.63M |
Market Cap | 55.26M |
P/E Ratio | -100.00K |
Shares Outstanding | 54.72M |
Revenue | 10.32M |
EPS | -1.74 |
Dividend (Yield %) | N/A |
Beta | 0.83 |
Next Earnings Date | Mar 22, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 0.9794 | -0.0010 | -0.10% | 0.9804 | 1.0097 | 0.9781 |
Feb 2, 2023 | 0.9784 | 0.0170 | 1.77% | 0.9614 | 0.9902 | 0.9614 |
Feb 1, 2023 | 0.9615 | -0.0063 | -0.65% | 0.9678 | 0.9804 | 0.9507 |
Jan 31, 2023 | 0.9705 | 0.0098 | 1.02% | 0.9607 | 0.9804 | 0.9311 |
Jan 30, 2023 | 0.9509 | -0.0028 | -0.29% | 0.9537 | 0.9706 | 0.9309 |
Jan 27, 2023 | 0.9804 | 0.0200 | 2.08% | 0.9604 | 0.9804 | 0.9604 |
Jan 26, 2023 | 0.9606 | 0.0089 | 0.94% | 0.9517 | 0.9804 | 0.9507 |
Jan 25, 2023 | 0.9607 | 0.0198 | 2.10% | 0.9409 | 1.0000 | 0.9310 |
Jan 24, 2023 | 0.9431 | -0.0274 | -2.82% | 0.9705 | 0.9707 | 0.9370 |
Jan 23, 2023 | 0.9626 | -0.0273 | -2.76% | 0.9899 | 0.9902 | 0.9606 |
Jan 20, 2023 | 0.9804 | 0.0004 | 0.04% | 0.9800 | 1.0000 | 0.9702 |
Jan 19, 2023 | 0.9902 | 0.0199 | 2.05% | 0.9703 | 1.0098 | 0.9703 |
Jan 18, 2023 | 0.9803 | -0.0193 | -1.93% | 0.9996 | 1.0392 | 0.9564 |
Jan 17, 2023 | 0.9998 | 0.0202 | 2.06% | 0.9796 | 1.0196 | 0.9602 |
Jan 13, 2023 | 0.9706 | 0.0470 | 5.09% | 0.9236 | 1.0000 | 0.9236 |
Jan 12, 2023 | 0.9412 | 0.0495 | 5.55% | 0.8917 | 0.9607 | 0.8916 |
Jan 11, 2023 | 0.9313 | 0.0439 | 4.95% | 0.8874 | 0.9510 | 0.8819 |
Jan 10, 2023 | 0.8921 | 0.0295 | 3.42% | 0.8626 | 0.9018 | 0.8626 |
Jan 9, 2023 | 0.8708 | -0.0308 | -3.42% | 0.9016 | 0.9216 | 0.8625 |
Jan 6, 2023 | 0.8626 | 0.0443 | 5.41% | 0.8183 | 0.8848 | 0.8153 |
HOOKIPA Pharma Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Total revenue | 0 | 7.629 | 11.942 | 19.584 | 18.448 |
Revenue | 0 | 7.629 | 11.942 | 19.584 | 18.448 |
Total Operating Expense | 14.157 | 28.809 | 63.027 | 72.869 | 100.122 |
Selling/General/Admin. Expenses, Total | 4.385 | 6.844 | 17.809 | 19.715 | 19.172 |
Research & Development | 9.772 | 21.965 | 44.854 | 52.738 | 80.518 |
Operating Income | -14.157 | -21.18 | -51.085 | -53.285 | -81.674 |
Interest Income (Expense), Net Non-Operating | -0.606 | -0.778 | 0.71 | -0.386 | -0.871 |
Other, Net | 2.044 | 5.745 | 7.338 | 9.589 | 6.881 |
Net Income Before Taxes | -12.719 | -16.213 | -43.037 | -44.082 | -75.664 |
Net Income After Taxes | -12.723 | -16.237 | -43.037 | -44.082 | -75.665 |
Net Income Before Extra. Items | -12.723 | -16.237 | -43.037 | -44.082 | -75.665 |
Net Income | -12.723 | -16.237 | -43.037 | -44.082 | -75.665 |
Income Available to Common Excl. Extra. Items | -12.723 | -16.237 | -43.037 | -44.082 | -75.665 |
Income Available to Common Incl. Extra. Items | -12.723 | -16.237 | -43.037 | -44.082 | -75.665 |
Diluted Net Income | -12.723 | -16.237 | -43.037 | -44.082 | -75.665 |
Diluted Weighted Average Shares | 25.4085 | 25.4085 | 17.8599 | 26.0391 | 32.8336 |
Diluted EPS Excluding Extraordinary Items | -0.50074 | -0.63904 | -2.4097 | -1.69292 | -2.3045 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -0.50074 | -0.63904 | -2.4097 | -1.69292 | -2.3045 |
Depreciation / Amortization | 0.364 | 0.416 | 0.432 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 5.301 | 5.378 | 3.874 | 3.895 | 1.445 |
Revenue | 5.301 | 5.378 | 3.874 | 3.895 | 1.445 |
Total Operating Expense | 24.473 | 24.667 | 25.04 | 25.942 | 21.592 |
Selling/General/Admin. Expenses, Total | 4.309 | 5.095 | 4.342 | 3.523 | 4.972 |
Research & Development | 20.164 | 19.572 | 20.698 | 22.419 | 16.62 |
Operating Income | -19.172 | -19.289 | -21.166 | -22.047 | -20.147 |
Interest Income (Expense), Net Non-Operating | -0.212 | -0.211 | -0.227 | -0.221 | -0.236 |
Other, Net | 2.146 | 2.347 | 1.354 | 1.033 | 2.415 |
Net Income Before Taxes | -17.238 | -17.153 | -20.039 | -21.235 | -17.968 |
Net Income After Taxes | -17.238 | -17.153 | -20.04 | -21.235 | -17.968 |
Net Income Before Extra. Items | -17.238 | -17.153 | -20.04 | -21.235 | -17.968 |
Net Income | -17.238 | -17.153 | -20.04 | -21.235 | -17.968 |
Income Available to Common Excl. Extra. Items | -17.238 | -17.153 | -20.04 | -21.235 | -17.968 |
Income Available to Common Incl. Extra. Items | -17.238 | -17.153 | -20.04 | -21.235 | -17.968 |
Diluted Net Income | -17.238 | -17.153 | -20.04 | -21.235 | -17.968 |
Diluted Weighted Average Shares | 29.7883 | 32.8043 | 32.8744 | 32.8882 | 38.603 |
Diluted EPS Excluding Extraordinary Items | -0.57868 | -0.52289 | -0.60959 | -0.64567 | -0.46546 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.57868 | -0.52289 | -0.60959 | -0.64567 | -0.46546 |
- Annual
- Quarterly
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Total Current Assets | 69.958 | 62.311 | 128.017 | 171.504 | 102.135 |
Cash and Short Term Investments | 61.362 | 48.58 | 113.151 | 142.743 | 65.921 |
Cash & Equivalents | 61.362 | 48.58 | 113.151 | 142.743 | 65.921 |
Total Receivables, Net | 6.52 | 4.919 | 9.727 | 20.657 | 21.166 |
Accounts Receivable - Trade, Net | 0 | 4.919 | 1.537 | 5.542 | 6.895 |
Prepaid Expenses | 2.076 | 8.812 | 5.139 | 8.104 | 14.482 |
Total Assets | 73.732 | 68.251 | 143.745 | 187.817 | 126.045 |
Property/Plant/Equipment, Total - Net | 3.575 | 4.337 | 14.603 | 13.969 | 22.115 |
Property/Plant/Equipment, Total - Gross | 5.116 | 6.403 | 18.049 | 19.066 | 28.481 |
Accumulated Depreciation, Total | -1.541 | -2.066 | -3.446 | -5.097 | -6.366 |
Other Long Term Assets, Total | 0.199 | 1.603 | 1.125 | 2.344 | 1.795 |
Total Current Liabilities | 4.035 | 14.695 | 14.755 | 21.143 | 27.654 |
Accounts Payable | 1.477 | 3.656 | 0.944 | 8.009 | 8.762 |
Accrued Expenses | 2.558 | 4.42 | 5.262 | 7.138 | 9.598 |
Notes Payable/Short Term Debt | 0 | 0 | 1.224 | 0 | 0 |
Other Current Liabilities, Total | 0 | 6.619 | 7.166 | 5.841 | 6.481 |
Total Liabilities | 11.614 | 23.852 | 25.846 | 31.694 | 36.453 |
Total Long Term Debt | 3.738 | 4.392 | 3.862 | 4.795 | 2.219 |
Long Term Debt | 3.738 | 4.392 | 3.495 | 4.537 | 2.219 |
Other Liabilities, Total | 3.841 | 4.765 | 7.229 | 5.756 | 6.58 |
Total Equity | 62.118 | 44.399 | 117.899 | 156.123 | 89.592 |
Redeemable Preferred Stock | 104.774 | 104.774 | 0 | ||
Common Stock | 0 | 0 | 0.003 | 0.003 | 0.003 |
Additional Paid-In Capital | 2.451 | 3.327 | 225.568 | 309.288 | 317.135 |
Retained Earnings (Accumulated Deficit) | -43.745 | -59.982 | -103.019 | -147.101 | -222.766 |
Other Equity, Total | -1.362 | -3.72 | -4.653 | -6.067 | -4.78 |
Total Liabilities & Shareholders’ Equity | 73.732 | 68.251 | 143.745 | 187.817 | 126.045 |
Total Common Shares Outstanding | 25.4085 | 25.4085 | 25.5661 | 29.7684 | 31.2032 |
Current Port. of LT Debt/Capital Leases | 0.159 | 0.155 | 2.813 | ||
Capital Lease Obligations | 0.367 | 0.258 | 0 | ||
Preferred Stock - Non Redeemable, Net | 0 | ||||
Other Current Assets, Total | 0.566 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 153.34 | 143.451 | 118.577 | 102.135 | 171.079 |
Cash and Short Term Investments | 127.716 | 102.523 | 82.269 | 65.921 | 140.825 |
Cash & Equivalents | 127.716 | 102.523 | 82.269 | 65.921 | 140.825 |
Total Receivables, Net | 17.881 | 20.9 | 20.399 | 21.166 | 16.325 |
Accounts Receivable - Trade, Net | 4.285 | 4.923 | 2.52 | 6.895 | 0.703 |
Prepaid Expenses | 7.743 | 20.028 | 15.909 | 14.482 | 13.374 |
Total Assets | 169.941 | 166.156 | 142.172 | 126.045 | 195.711 |
Property/Plant/Equipment, Total - Net | 13.103 | 19.517 | 20.935 | 22.115 | 22.413 |
Other Long Term Assets, Total | 3.498 | 3.188 | 2.66 | 1.795 | 2.219 |
Total Current Liabilities | 20.116 | 33.876 | 26.638 | 27.654 | 31.228 |
Accounts Payable | 8.053 | 10.865 | 10.1 | 8.762 | 6.708 |
Accrued Expenses | 5.432 | 15.857 | 10.238 | 9.598 | 9.607 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 3.375 |
Current Port. of LT Debt/Capital Leases | 0.141 | 2.812 | 2.867 | 2.813 | 0 |
Other Current Liabilities, Total | 6.49 | 4.342 | 3.433 | 6.481 | 11.538 |
Total Liabilities | 29.886 | 40.222 | 34.086 | 36.453 | 47.782 |
Total Long Term Debt | 4.857 | 2.327 | 2.374 | 2.219 | 1.766 |
Long Term Debt | 4.557 | 2.127 | 2.174 | 2.219 | 1.766 |
Capital Lease Obligations | 0.3 | 0.2 | 0.2 | 0 | |
Other Liabilities, Total | 4.913 | 4.019 | 5.074 | 6.58 | 14.788 |
Total Equity | 140.055 | 125.934 | 108.086 | 89.592 | 147.929 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
Common Stock | 0.003 | 0.003 | 0.003 | 0.003 | 0.005 |
Additional Paid-In Capital | 310.934 | 313.673 | 315.394 | 317.135 | 393.925 |
Retained Earnings (Accumulated Deficit) | -164.339 | -181.492 | -201.532 | -222.766 | -240.734 |
Other Equity, Total | -6.543 | -6.25 | -5.779 | -4.78 | -5.267 |
Total Liabilities & Shareholders’ Equity | 169.941 | 166.156 | 142.172 | 126.045 | 195.711 |
Total Common Shares Outstanding | 29.8144 | 29.8716 | 29.9038 | 31.2032 | 54.6925 |
Property/Plant/Equipment, Total - Gross | 25.351 | 27.176 | 28.481 | 29.044 | |
Accumulated Depreciation, Total | -5.834 | -6.241 | -6.366 | -6.631 | |
Other Current Assets, Total | 0.566 | 0.555 |
- Annual
- Quarterly
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -12.723 | -16.237 | -43.037 | -44.082 | -75.665 |
Cash From Operating Activities | -11.913 | -14.998 | -41.731 | -39.339 | -66.016 |
Cash From Operating Activities | 0.398 | 0.64 | 1.443 | 4.15 | 4.64 |
Non-Cash Items | 0.725 | 0.874 | 7.241 | 8.71 | 8.87 |
Cash Taxes Paid | 0.004 | 0.024 | 0 | 0 | 0.001 |
Cash Interest Paid | 0.06 | 0.071 | 0.064 | 0.097 | 0.048 |
Changes in Working Capital | -0.313 | -0.275 | -7.378 | -8.117 | -3.861 |
Cash From Investing Activities | -1.297 | -2.15 | -1.999 | -2.371 | -12.581 |
Capital Expenditures | -1.297 | -2.15 | -1.999 | -2.371 | -12.581 |
Cash From Financing Activities | 58.892 | 6.873 | 109.751 | 73.42 | -0.235 |
Issuance (Retirement) of Stock, Net | 58.892 | 6.864 | 112.03 | 75.063 | 0.203 |
Issuance (Retirement) of Debt, Net | 0 | 0.009 | -2.279 | -1.419 | -0.438 |
Foreign Exchange Effects | 2.494 | -2.507 | -1.026 | -2.108 | 2.567 |
Net Change in Cash | 48.176 | -12.782 | 64.995 | 29.602 | -76.265 |
Financing Cash Flow Items | -0.224 | 0 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -17.238 | -34.391 | -54.43 | -75.665 | -17.968 |
Cash From Operating Activities | -14.397 | -35.129 | -52.773 | -66.016 | 1.733 |
Cash From Operating Activities | 1.103 | 2.321 | 3.412 | 4.64 | 1.078 |
Non-Cash Items | 1.521 | 4.181 | 5.901 | 8.87 | 1.695 |
Cash Taxes Paid | 0 | 0 | 0.001 | 0.001 | 0 |
Cash Interest Paid | 0 | 0.024 | 0.024 | 0.048 | 0 |
Changes in Working Capital | 0.217 | -7.24 | -7.656 | -3.861 | 16.928 |
Cash From Investing Activities | -0.33 | -4.954 | -7.44 | -12.581 | -1.828 |
Capital Expenditures | -0.33 | -4.954 | -7.44 | -12.581 | -1.828 |
Cash From Financing Activities | 0.101 | 0.186 | 0.175 | -0.235 | 75.293 |
Issuance (Retirement) of Stock, Net | 0.125 | 0.237 | 0.239 | 0.203 | 75.313 |
Issuance (Retirement) of Debt, Net | -0.024 | -0.051 | -0.064 | -0.438 | -0.02 |
Foreign Exchange Effects | -0.406 | -0.327 | -0.442 | 2.567 | -0.307 |
Net Change in Cash | -15.032 | -40.224 | -60.48 | -76.265 | 74.891 |
Financing Cash Flow Items | 0 | 0 | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Deep Track Capital LP | Hedge Fund | 9.6259 | 5035998 | 0 | 2022-09-30 | MED |
Fidelity Management & Research Company LLC | Investment Advisor | 9.6252 | 5035645 | -638566 | 2022-09-30 | LOW |
EcoR1 Capital, LLC | Hedge Fund | 9.5571 | 5000000 | 0 | 2022-09-30 | MED |
Redmile Group, LLC | Investment Advisor/Hedge Fund | 8.7204 | 4562248 | 0 | 2022-09-30 | LOW |
Gilead Sciences Inc | Corporation | 7.1859 | 3759465 | 1666666 | 2022-02-15 | LOW |
Sofinnova Partners | Venture Capital | 6.0075 | 3142956 | 360 | 2022-04-13 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 4.5883 | 2400481 | 0 | 2022-09-30 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 3.5354 | 1849616 | 0 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.371 | 1763621 | 111890 | 2022-09-30 | LOW |
Forbion Capital Partners | Venture Capital | 1.7737 | 927966 | -1213921 | 2021-12-31 | LOW |
BofA Global Research (US) | Research Firm | 0.8569 | 448296 | -2997 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7509 | 392825 | 0 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 0.7303 | 382095 | -320643 | 2022-09-30 | HIGH |
RBC Capital Markets Wealth Management | Research Firm | 0.5558 | 290756 | 28263 | 2022-09-30 | LOW |
Takeda Pharmaceutical Co Ltd | Corporation | 0.5556 | 290693 | -1042895 | 2021-07-22 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.492 | 257423 | 3437 | 2022-09-30 | LOW |
EQT Life Sciences | Venture Capital | 0.4143 | 216776 | 26704 | 2021-06-30 | LOW |
Bridgeway Capital Management, LLC | Investment Advisor | 0.3838 | 200800 | 123500 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3339 | 174690 | 565 | 2022-09-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.2718 | 142200 | 47500 | 2022-09-30 | HIGH |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group +485000+
Trader
65000+
Klien aktif per bulan
$48000000+
Volume investasi per bulan
$28000000+
Coba sekarang Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Pharmaceuticals (NEC) |
430 East 29Th Street
14Th Floor
NEW YORK
NEW YORK 10016-8367
US
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 485.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com